Contera Pharma A/S, a biotech company developing innovative therapies to treat neurological disorders, announce enrolment of the last patient in its Phase 2b clinical trial ASTORIA . The trial aims to evaluate the efficacy of JM-010, a novel therapeutic solution designed to specifically address the pathophysiology underlying Parkinson’s Disease dyskinesia. This milestone is an important achievement for the continued development of JM-010. “We are excited to reach this pivotal moment in our clinical trial for JM-010. The enrolment of the last patient marks a significant step forward in our mission to bring innovative and effective treatments to those patients in need", said Kenneth Vielsted Christensen, CSO and Head of R&D, Contera Pharma.” The completion of patient enrolment represents a key achievement in the overall progress of the ASTORIA trial, showcasing the commitment and dedication of the clinical investigators and the participating patients. Topline results from the European JM-010 study are expected second half of 2024. “I am thrilled to announce this milestone and looking forward to communicating the study results during the latter half this year, said Thomas Sager, CEO, Contera Pharma. “On behalf of the whole Contera Pharma team, I would also like to extend our gratitude to the patients, healthcare professionals, our alliance partner Bukwang and all stakeholders who have contributed to reaching this important stage.” |